AT230878B - Process for the preparation of new aliphatic α-hydroxycarboxylic acids substituted by an aromatic radical and derivatives thereof - Google Patents
Process for the preparation of new aliphatic α-hydroxycarboxylic acids substituted by an aromatic radical and derivatives thereofInfo
- Publication number
- AT230878B AT230878B AT384161A AT384161A AT230878B AT 230878 B AT230878 B AT 230878B AT 384161 A AT384161 A AT 384161A AT 384161 A AT384161 A AT 384161A AT 230878 B AT230878 B AT 230878B
- Authority
- AT
- Austria
- Prior art keywords
- sep
- acid
- preparation
- derivatives
- hydroxycarboxylic acids
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 title claims description 5
- 150000007513 acids Chemical group 0.000 title claims description 4
- 125000001931 aliphatic group Chemical group 0.000 title claims description 4
- 238000010992 reflux Methods 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal cyanide Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- UMYZWICEDUEWIM-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)propan-2-one Chemical compound COC1=CC=C(CC(C)=O)C=C1OC UMYZWICEDUEWIM-UHFFFAOYSA-N 0.000 description 2
- XTCWGZKPNHWUSF-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-2-hydroxy-2-methylpropanenitrile Chemical compound COC1=CC=C(CC(C)(O)C#N)C=C1OC XTCWGZKPNHWUSF-UHFFFAOYSA-N 0.000 description 2
- XJMRYDACEIUIHX-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-2-hydroxy-2-methylpropanoic acid Chemical compound COC1=CC=C(CC(C)(O)C(O)=O)C=C1OC XJMRYDACEIUIHX-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- FCFNKTVTWIPYIT-UHFFFAOYSA-N 2-acetyloxy-3-(3,4-diacetyloxyphenyl)-2-methylpropanoic acid Chemical compound C(C)(=O)OC(C(=O)O)(C)CC1=CC(=C(C=C1)OC(C)=O)OC(C)=O FCFNKTVTWIPYIT-UHFFFAOYSA-N 0.000 description 1
- FDCRDMCJFYSQRT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-2-hydroxy-2-methylpropanoic acid Chemical compound OC=1C=C(CC(C(=O)O)(O)C)C=CC1O FDCRDMCJFYSQRT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung von neuen, durch einen aromatischen Rest substituierten aliphatischen (l- Hydroxycarbonsäuren und Derivaten derselben
Die Erfindung betrifft ein Verfahren zur Herstellung von Verbindungen, die sich zur Verwendung in antihypertonischen Mitteln eignen, u. zw. auf die Herstellung von arylsubstituierten aliphatischen a-Hy- droxycarbonsäuren, die als Inhibitoren für Säugetier-Decarboxylase wirken. Diese Eigenschaft ist zur Bildung von antihypertonischen Mitteln wertvoll. Einige dieser Verbindungen wirken selbst als antihypertonische Mittel.
Die erfindungsgemäss hergestellten Verbindungen haben die allgemeine Formel
EMI1.1
in der rut einen geradkettigen niederen Alkylrest bedeutet, und umfassen auch die Alkali- und Ammoniumsalze sowie die Ester.
Die Verbindungen können gemäss der Erfindung aus einem Keton der allgemeinen Formel
EMI1.2
dargestellt werden, in der Rl die obige Bedeutung hat.
Die erfindungsgemässeHerstellung der Verbindungen kann an Hand der Herstellung von 2- (3', 4*-Dihydroxybenzyl)-milchsaure (V) aus 1- (3', 4'-Dimethoxyphenyl)-2-propanon (I) durch das folgende Reaktionsschema dargestellt werden :
<Desc/Clms Page number 2>
EMI2.1
EMI2.2
<Desc/Clms Page number 3>
Die erfindungsgemäss hergestellten Verbindungen inhibieren Säugetier-Decarboxylase, wenn sie oral in Tagesdosen von etwa 0, 25 bis etwa 10 g, vorzugsweise verteilt über den Tag, verabfolgt werden. Die bevorzugte Dosis liegt im Bereich von etwa 0, 5 bis 5 g je Tag. Diese Verbindungen können in Gelatinekapseln da. gereicht werden, die etwa 0, 1-0,5 g Wirkstoff enthalten, sowie auch in Tabletten, die etwa
EMI3.1
wässeriger Suspensionen oral verabfolgt werden. Anderseits können die Verbindungen auch in Form ihrer
Alkalisalze in sterilen Lösungen in geeigneten Lösungsmitteln, wie Wasser, in Tagesmengen von etwa 0, 1 bis 2 g, die vorzugsweise über den Tag verteilt werden, parenteral verabfolgt werden.
Wenn die Verbindungen in Kombination oder im Gemisch mit Mitteln verwendet werden, die einen starken Entzug von
Brenzkatechinaminen aus dem Herz- und Hirngewebe bewirken, besitzen sie antihypertonische Wirkung.
Einige dieser Verbindungen sind auch für sich selbst antihypertonisch wirksam, möglicherweise weil sie die beiden genannten Eigenschaften besitzen.
Beispiel : a) 2- (3',4'-Dimethoxybenzyl)-lactonitril: EineLösungvon63g (0,967Mol)Kaliumcyanidund126g(0,649Mol)1-(3',4'-Dimethoxyphenyl)- - 2-propanon (I) in 145 cm3 Wasser und 363 cm3 Methanol wird tropfenweise im Verlaufe von 6 h mit 157, 5 cm3 400/oiger Schwefelsäure versetzt. Während des Zusatzes der Schwefelsäure wird das Gemisch
EMI3.2
(3', 4'-Dimethoxybenzyl)-lactonitril47, 7 g (0, 215 Mol) 2-(3',4'-Dimethoxybenzyl)-lactonitril (II), hergestellt nach Abschnitt a), werden mit 108 cm3 36% iger Salzsäure versetzt. Das Gemisch wird 5 h am Rückflusskühler erhitzt, dann auf Raumtemperatur gekühlt und mit Äthylacetat extrahiert.
Der Äthylacetatextrakt wird mit Wasser gewaschen, mit 1 g Entfärbungskohle ("Nuchar C") behandelt, filtriert und im Vakuum auf ein kleines Flüssigkeitsvolumen eingeengt, welches Kristalle enthält. Beim Zusatz von 100 cm3 Äther kristallisiert das Produkt vollständig aus. Man lässt das Gemisch 16 h stehen, filtriert und wäscht und trocknet die rohe 2- (3', 4'-Dimethoxybenzyl)-milchsäure. Ausbeule 24, 84 g ; Fp = 118-121 C; #CH3OH m (E% 339), max 278 mil (E% 112), 283 mg (Schulter) (E% 102).
- c) 2-Acetoxy-2- (3', 4'-diacetoxybenzyl)-propionsäure : 13, 85 g (0, 0627 Mol) der nach Abschnitt b) hergestellten 2-(3',4'-Dimethoxybenzyl)-milchsäure (III) werden mit 78,5 cm3 58%iger Bromwasserstoffsäure versetzt. Das Gemisch wird mit Stickstoff ausgeblasen, 2 h am Rückflusskühler erhitzt und im Vakuum eingeengt. Der Rückstand wird in tert.-Butanol gelöst und im Vakuum zur Trockne eingedampft. Dieses Verfahren wird wiederholt.
Der schliesslich erhaltene Rückstand von roher 2-(3',4'-Dihydroxybenzyl)-milchsäure wird in 65 cm3 Pyridin gelöst und die Lösung, unter Kühlung des Reaktionskolbens von aussen her auf eine Innentemperatur im Bereich von 10 bis 20 C, mit 65 cm3 Essigsäureanhydrid versetzt. Das Reaktionsgemisch wird bei Raumtemperatur 16 h stehen gelassen und dann im Vakuum zu einem Harz eingedampft. Das Harz wird in Äthylacetat gelöst, und die Lösung wird nacheinander mit verdünnter Salzsäure, Wasser und gesättigter Kochsalzlösung extrahiert, über wasserfreiem Magnesiumsulfat getrocknet, im Vakuum eingeengt und der Ruckstand aus einer Lösung von 501o Benzol und 50% Hexan umkristallisiert.
Man erhält 2-Acetoxy-
EMI3.3
Bande), 5, 7 li-5, 75 u, 5,85 li, 6,25 p und 6,61 u.
EMI3.4
<tb>
<tb>
Analyse <SEP> : <SEP>
<tb> Berechnet <SEP> für <SEP> C <SEP> H <SEP> 0 <SEP> : <SEP> C <SEP> = <SEP> 56, <SEP> 80lu <SEP> ; <SEP> H <SEP> = <SEP> 5, <SEP> 36lu <SEP> ; <SEP>
<tb> gefunden <SEP> : <SEP> C <SEP> = <SEP> 56, <SEP> 72% <SEP> ; <SEP> H <SEP> = <SEP> 5, <SEP> 66%. <SEP>
<tb>
<Desc/Clms Page number 4>
EMI4.1
stellt nach Abschnitt c), 86,3 cm3 2, 5n-Salzsäure und 30 cm3 Wasser wird mit Stickstoff gespült und 2 h unter einer Stickstoffatmosphäre auf Rückflusstemperatur erhitzt. Das Reaktionsgemisch wird im Vakuum
EMI4.2
EMI4.3
<tb>
<tb> 4'-DiAnalyse <SEP> :
<tb> Berchnet <SEP> für <SEP> C18H12O5 <SEP> : <SEP> C=56,60%; <SEP> H=5,7%;
<tb> gefunden: <SEP> C=56,64% <SEP> ; <SEP> H=5,97%.
<tb>
Dieses Produkt wird durch Lösen in Äther und langsames Abdampfen des Lösungsmittels gereinigt, wobei lange, durchsichtige Nadeln entstehen ; Fp = 95 - 10IoC (Zers.).
<Desc / Clms Page number 1>
Process for the preparation of new aliphatic (1-hydroxycarboxylic acids and derivatives thereof substituted by an aromatic radical)
The invention relates to a process for the preparation of compounds suitable for use in antihypertensive agents, u. between the production of aryl-substituted aliphatic a-hydroxycarboxylic acids, which act as inhibitors for mammalian decarboxylase. This property is valuable for the formation of antihypertensive agents. Some of these compounds act as antihypertensive agents by themselves.
The compounds prepared according to the invention have the general formula
EMI1.1
in rut means a straight-chain lower alkyl radical, and also include the alkali and ammonium salts and the esters.
According to the invention, the compounds can be prepared from a ketone of the general formula
EMI1.2
are shown, in which Rl has the above meaning.
The preparation according to the invention of the compounds can be illustrated by the preparation of 2- (3 ', 4 * -dihydroxybenzyl) lactic acid (V) from 1- (3', 4'-dimethoxyphenyl) -2-propanone (I) by the following reaction scheme will :
<Desc / Clms Page number 2>
EMI2.1
EMI2.2
<Desc / Clms Page number 3>
The compounds prepared according to the invention inhibit mammalian decarboxylase when they are administered orally in daily doses of about 0.25 to about 10 g, preferably divided over the day. The preferred dose is in the range of about 0.5 to 5 g per day. These compounds can be found in gelatin capsules. are served, which contain about 0.1-0.5 g of active ingredient, as well as tablets that contain about
EMI3.1
aqueous suspensions can be administered orally. On the other hand, the connections can also be in the form of their
Alkali salts in sterile solutions in suitable solvents, such as water, are administered parenterally in daily amounts of about 0.1 to 2 g, which are preferably distributed over the day.
If the compounds are used in combination or in a mixture with agents that cause a strong withdrawal of
Catecholamines from the heart and brain tissue have an antihypertensive effect.
Some of these compounds are antihypertensive on their own, possibly because they have both of these properties.
Example: a) 2- (3 ', 4'-Dimethoxybenzyl) -lactonitrile: A solution of 63 g (0.967 mol) potassium cyanide and 126 g (0.649 mol) 1- (3', 4'-dimethoxyphenyl) - - 2-propanone (I) in 145 cm3 157.5 cm3 of 400% sulfuric acid are added dropwise to water and 363 cm3 of methanol over the course of 6 h. During the addition of the sulfuric acid, the mixture becomes
EMI3.2
(3 ', 4'-Dimethoxybenzyl) -lactonitrile47.7 g (0.215 mol) 2- (3', 4'-dimethoxybenzyl) -lactonitrile (II), prepared according to section a), are 36% strength with 108 cm3 Hydrochloric acid added. The mixture is refluxed for 5 h, then cooled to room temperature and extracted with ethyl acetate.
The ethyl acetate extract is washed with water, treated with 1 g of decolorizing charcoal ("Nuchar C"), filtered and concentrated in vacuo to a small volume of liquid which contains crystals. When adding 100 cm3 of ether, the product crystallizes out completely. The mixture is left to stand for 16 hours, filtered and washed and the crude 2- (3 ', 4'-dimethoxybenzyl) lactic acid is dried. Bulge 24, 84 g; M.p. 118-121 C; # CH3OH m (E% 339), max 278 mil (E% 112), 283 mg (shoulder) (E% 102).
- c) 2-Acetoxy-2- (3 ', 4'-diacetoxybenzyl) propionic acid: 13.85 g (0.0627 mol) of the 2- (3', 4'-dimethoxybenzyl) lactic acid prepared according to section b) (III) 78.5 cm3 of 58% hydrobromic acid are added. The mixture is blown out with nitrogen, heated on the reflux condenser for 2 h and concentrated in vacuo. The residue is dissolved in tert-butanol and evaporated to dryness in vacuo. This procedure is repeated.
The residue of crude 2- (3 ', 4'-dihydroxybenzyl) lactic acid finally obtained is dissolved in 65 cm3 of pyridine and the solution, with cooling of the reaction flask from the outside to an internal temperature in the range of 10 to 20 ° C., is 65 cm3 Acetic anhydride added. The reaction mixture is left at room temperature for 16 hours and then evaporated to a resin in vacuo. The resin is dissolved in ethyl acetate and the solution is extracted successively with dilute hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, concentrated in vacuo and the residue is recrystallized from a solution of 5010 benzene and 50% hexane.
2-acetoxy-
EMI3.3
Band), 5, 7 p-5, 75 u, 5.85 p, 6.25 p and 6.61 u.
EMI3.4
<tb>
<tb>
Analysis <SEP>: <SEP>
<tb> Calculates <SEP> for <SEP> C <SEP> H <SEP> 0 <SEP>: <SEP> C <SEP> = <SEP> 56, <SEP> 80lu <SEP>; <SEP> H <SEP> = <SEP> 5, <SEP> 36lu <SEP>; <SEP>
<tb> found <SEP>: <SEP> C <SEP> = <SEP> 56, <SEP> 72% <SEP>; <SEP> H <SEP> = <SEP> 5, <SEP> 66%. <SEP>
<tb>
<Desc / Clms Page number 4>
EMI4.1
according to section c), 86.3 cm3 of 2, 5N hydrochloric acid and 30 cm3 of water are flushed with nitrogen and heated to reflux temperature for 2 h under a nitrogen atmosphere. The reaction mixture is in vacuo
EMI4.2
EMI4.3
<tb>
<tb> 4'-Dianalysis <SEP>:
<tb> Calculated <SEP> for <SEP> C18H12O5 <SEP>: <SEP> C = 56.60%; <SEP> H = 5.7%;
<tb> found: <SEP> C = 56.64% <SEP>; <SEP> H = 5.97%.
<tb>
This product is purified by dissolving it in ether and slowly evaporating the solvent, producing long, transparent needles; M.p. 95-1010C (dec.).
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US230878XA | 1960-05-25 | 1960-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT230878B true AT230878B (en) | 1963-12-30 |
Family
ID=21813067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT384161A AT230878B (en) | 1960-05-25 | 1961-05-16 | Process for the preparation of new aliphatic α-hydroxycarboxylic acids substituted by an aromatic radical and derivatives thereof |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT230878B (en) |
-
1961
- 1961-05-16 AT AT384161A patent/AT230878B/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2810253A1 (en) | NEW CHALCONDERIVATES AND THE PROCESS FOR THEIR PRODUCTION | |
| DE2047658C3 (en) | 2-Styryl- and 2-Phenyläthinylbenzylamine derivatives, processes for their preparation and medicaments containing them | |
| AT230878B (en) | Process for the preparation of new aliphatic α-hydroxycarboxylic acids substituted by an aromatic radical and derivatives thereof | |
| DE2000030B2 (en) | 3 alkoxy and 3 phenoxy 2 (diphenyl hydroxy) methyl propylamine and medicinal products containing them | |
| CH441291A (en) | Process for the production of organic amines | |
| DE1158082B (en) | Process for the preparation of alkylenediamine derivatives and their salts | |
| AT227256B (en) | Process for the production of new aminoindanes and their salts | |
| AT323154B (en) | PROCESS FOR THE PRODUCTION OF NEW 5-METHOXY-2-METHYLINDOL-3-ACETIC ACID DERIVATIVES AND OF THEIR SALTS | |
| AT259557B (en) | Process for the preparation of 3-aminoisoxazoles | |
| DE1900948C (en) | Cis- and trans-2-methyl-5- (3, 4, S-trimethoxybenzamidoJ-decahydroisoquinoline | |
| AT163638B (en) | Process for the preparation of methylchlorophenoxyalkylcarboxylic acid compounds | |
| AT208867B (en) | Process for the preparation of new substituted heterocyclic acid hydrazides | |
| AT354432B (en) | METHOD FOR PRODUCING 3-INDOLYLESSIC ACIDS | |
| CH227069A (en) | Process for the preparation of a cyclopentano-dimethyl-polyhydrophenanthrene-carboxylic acid. | |
| AT215417B (en) | Process for the preparation of new N-carbalkoxy- or -aralkoxyalkyl-β- (3,4-dihydroxyphenyl) -β-hydroxyethylamines and their salts | |
| AT337679B (en) | PROCESS FOR PRODUCING NEW DERIVATIVES OF 2-AMINO-INDANE | |
| AT146504B (en) | Process for the preparation of amides of pyrazine monocarboxylic acid. | |
| DE1443604C3 (en) | 1-Aminomethyl-1,2-dihydro-benzocyclobutene and some of its derivatives, salts of these compounds, processes for the preparation of these compounds and pharmaceutical preparations containing these compounds | |
| AT321289B (en) | Process for the preparation of new Diphenyläthanalkylaminen and their acid addition salts | |
| AT208349B (en) | Process for the preparation of new substituted acid hydrazides | |
| AT288399B (en) | Process for the preparation of new cinnamic acid amides | |
| DE1493567C3 (en) | Esters of alpha-alkylthyroxine derivatives and process for their preparation | |
| AT254855B (en) | Process for the preparation of new 3-amino-2,4,6-triiodobenzoic acid derivatives | |
| AT360990B (en) | METHOD FOR PRODUCING THE NEW 1-METHYL-4- (3-CARBOXY-10,11-DIHYDRO-5H-DIBENZO- (A, D) - -CYCLOHEPTEN-5-YLIDEN) -PIPERIDINE (10,11-DIHYDRO -3- CARBOXY-CYPROHEPTADIN), HIS N-OXIDS AND HIS SALTS | |
| AT338790B (en) | PROCESS FOR THE PRODUCTION OF NEW QUINOLINESSIC ACID DERIVATIVES AND THEIR SALT |